Human atrial myosin light chain 1 expression attenuates heart failure.

Area of Science:

• Cardiology
• Molecular Biology
• Physiology

Background:

• Patients with hypertrophic cardiomyopathy and congenital heart diseases often express atrial essential myosin light chains (ALC-1) in ventricles, replacing ventricular essential myosin light chains (VLC-1).
• An isoform shift from VLC-1 to ALC-1 correlates with enhanced cardiac contractility in transgenic models.

Purpose of the Study:

• To investigate if the beneficial effects of atrial myosin light chains (ALC-1) on cardiac contractility can mitigate contractile failure in an overloaded heart.
• To assess the impact of ALC-1 expression on cardiac function under conditions of induced cardiac hypertrophy.

Main Methods:

• Transgenic rats overexpressing human ALC-1 (TGR/hALC-1) and wild-type WKY rats underwent an aortocaval shunt operation to induce cardiac overload and hypertrophy.
• Cardiac contractility was evaluated using Langendorff heart preparations five weeks post-operation.
• Transgene expression levels were quantified.

Main Results:

• Both shunt-operated TGR/hALC-1 and WKY rats developed comparable cardiac hypertrophy.
• However, shunt-operated TGR/hALC-1 rats exhibited a less pronounced decline in cardiac contractility compared to WKY rats.
• Key parameters like developed left ventricular pressure and maximal velocity of pressure development/relaxation were significantly higher in shunt-operated TGR/hALC-1 rats.

Conclusions:

• The expression of atrial myosin light chains (ALC-1) demonstrates a beneficial effect on the overloaded hypertrophied heart.
• ALC-1 may play a protective role in attenuating cardiac dysfunction under conditions of significant cardiac stress.